Monogenic Inflammatory Disorders Go Unrecognized Lancet Rheumatology published a large cohort analysis using a genome-first approach with whole-exome sequencing, finding a prevalence of 1 in 4026 (159/640092) for monogenic disorders, half with inflammatory features. Only one https://t.co/bItqMXIoUH

Treat-to-Target has Excellent 10-Year Outcomes in RA Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/aWQgQAsoSI

Should You Use Low Dose Naltrexone? A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/sC7kteQVMZ

Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/1J4SjcqF8u

REVEAL study enrolled 418 early microscopic polyangiitis pts - High baseline (Pre-Rx) neutrophil-to-lymphocyte ratio (NLR > 10) was assoc w/ signif higer Dz activity (BVAS), alveolar hemorrhage, poor renal function, reduced survival & higher infection-related mortality (P = https://t.co/wYBOz00GGB

FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/E0kL3j931Z

Biologic safety. Vasculitis mimics. What to do with seropositive arthralgia. RheumNow Live 2027 tackles the decisions you face in clinic. Jan. 30–31 | Onsite + virtual Registration NOW OPEN. Early Bird Pricing through 12/15/2026. https://t.co/zYYC2350tE https://t.co/mPI1o7sEcx

Treat-to-Target has Excellent 10-Year Outcomes in RA Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/sFI67Wo2fK

Monogenic Inflammatory Disorders Go Unrecognized Lancet Rheumatology published a large cohort analysis using a genome-first approach with whole-exome sequencing, finding a prevalence of 1 in 4026 (159/640092) for monogenic disorders, half with inflammatory features. Only one https://t.co/4v1PP41rii

Joint Disease in SLE Reconsidered A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x

RheumNow Live 2027 registration is NOW OPEN. GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote. Jan. 30–31 | Onsite + virtual Early Bird Pricing through 12/15/2026. See the agenda. Register: https://t.co/zYYC2350tE https://t.co/QeSxDPlIpv

Using Global Burden of Disease study data, an economic evaluation of 204 countries & territories, osteoarthritis & Alzheimers/dementias had highest health burden, but largest economic losses observed for combinations involving osteoarthritis, particularly osteoarthritis and https://t.co/0JgRgJAWy7

150 #Gout pts (56 yrs old; 33wks F/U; 21% drank EtOH, 29% obese, 5% MASLD) on allopurinol followed w/ labs. 30y (20%) had incr AST/ALT (87% mild, none severe). Allopurinol was cont 18/10 without change in AST/ALT. Allopurinol was not the primary cause of LFT elevation https://t.co/nBCACpvr5W

The FDA is reviewing Sun Pharma’s tildrakizumab (Ilumya), an IL-23 inhibitor, for use in active psoriatic arthritis, with an October 29, 2026 action (PDUFA) date. Decisons to be based on PsA INSPIRE-1 and INSPIRE-2 Phase 3 Studies https://t.co/iDWhub0k91 https://t.co/j8wQLxNCdA